The DCC protein and prognosis in colorectal cancer

New England Journal of Medicine

Volumn 335, Issue 23, 1996, Pages 1727-1732

  Shibata, David ^a   Reale, Michael A ^c   Lavin, Philip ^d   Silverman, Mark ^e   Fearon, Eric R ^f   Steele Jr , Glenn ^a   Jessup, John M ^a   Loda, Massimo ^b   Summerhayes, Ian C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Boston Biostatistics Research Foundation   (United States)

^e LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

ALLELE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 18Q; COLORECTAL CANCER; GENE ACTIVATION; GENE DELETION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

AGED; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, DCC; HUMANS; IMMUNOHISTOCHEMISTRY; LIFE TABLES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0029955460     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199612053352303     Document Type: Article

References (46)

1. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330:1136-42.
2. O'Connell MJ, Schaid DJ, Ganju V, Cunningham J, Kovach JS, Thibodeau SN. Current status of adjuvant chemotherapy for colorectal cancer: can molecular markers play a role in predicting prognosis? Cancer 1992; 70:Suppl:1732-9.
3. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-87.
4. Gastrointestinal Tumor Study Group. Adjuvant therapy of colon cancer - results of a prospectively randomized trial. N Engl J Med 1984;310: 737-43.
5. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
6. Idem. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995;13:2936-43.
7. Fisher B, Wolmark N, Roc kette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:21-9.
8. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
9. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.I. Science 1996;271:350-3.
10. Reale MA, Hu G, Zafar AI, Getzenberg RH, Levine SM, Fearon ER. Expression and alternative splicing of the deleted in colrectal cancer (DCC) gene in normal and malignant tissues. Cancer Res 1994;54:4493-501.
11. Brown RW, Chirala R. Utility of microwave-citrate antigen retrieval in diagnostic immunohistochemistry. Mod Pathol 1995;8:515-20.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
13. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
14. Kodner IJ, Fry RD, Fleshman JW, Birnbaum EH. Colon, rectum, and anus. In: Schwartz SI, ed. Principles of surgery. 6th ed. New York: McGraw-Hill, 1994:1191-306.
15. Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990;247:49-56.
16. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989;244:207-11.
17. Scheck AC, Coons SW. Expression of the tumor suppressor gene DCC in human gliomas. Cancer Res 1993;53:5605-9.
18. Uchino S, Tsuda H, Noguchi M, et al. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res 1992;52:3099-102.
19. Kashiwaba M, Tamura G, Ishida M. Frequent loss of heterozygosity at the deleted in colorectal carcinoma gene locus and its association with histologic phenotypes in breast carcinoma. Virchows Arch 1995;426:441-6.
20. Lumadue JA, Griffin CA, Osman M, Hruban RH. Familial pancreatic cancer and the genetics of pancreatic cancer. Surg Clin North Am 1995; 75:845-55.
21. Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y. Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Res 1994;54:3007-10.
22. Cordon-Cardo C, Dalbagni G, Sarkis AS, Reuter VE. Genetic alterations associated with bladder cancer. Important Adv Oncol 1994;71-83.
23. Brewster SF, Gingell JC, Browne S, Brown KW. Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 1994;70:697-700.
24. Brewster SF, Browne S, Brown KW. Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. J Urol 1994;151:1073-7.
25. Murty VV, Li RG, Houldsworth J, et al. Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors. Oncogene 1994;9:3227-31.
26. Gima T, Kato H, Honda T, Imamura T, Sasazuki T, Wake N. DCC gene alteration in human endometrial carcinomas. Int J Cancer 1994;57: 480-5.
27. Enomoto T, Fujita M, Cheng C, et al. Loss of expression and loss of heterozygosity in the DCC gene in neoplasms of the human female reproductive tract. Br J Cancer 1995;71:462-7.
28. Miyake K, Inokuchi K, Nomura T. Expression of the DCC gene in human hematological malignancies. Leuk Lymphoma 1994;16:13-8.
29. Miyake K, Inokuchi K, Dan K, Nomura T. Alterations in the deleted in colorectal carcinoma gene in human primary leukemia. Blood 1993;82: 927-30.
30. Froggatt NJ, Leveson SH, Garner RC. Low frequency and late occurrence of p53 and dcc aberrations in colorectal tumours. J Cancer Res Clin Oncol 1995;121:7-15.
31. Iacopetta B, DiGrandi S, Dix B, Haig C, Soong R, House A. Loss of heterozygosity of tumour suppressor gene loci in human colorectal carcinoma. Eur J Cancer 1994;30A:664-70.
32. Gao X, Honn KV, Grignon D, Sakr W, Chen YQ. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 1993;53:2723-7.
33. Hohne MW, Halatsch ME, Kahl GF, Weinel RJ. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 1992;52:2616-9.
34. Hedrick L, Cho KR, Fearon ER, Wu TC, Kinzler KW, Vogelstein B. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 1994;8:1174-83.
35. Chuong CM, Jiang TX, Yin E, Widelitz RB. cDCC (chicken homologue to a gene deleted in colorectal carcinoma) is an epithelial adhesion molecule expressed in the basal cells and involved in epithelial-mesenchymal interaction. Dev Biol 1994;164:383-97.
36. Turley H, Pezzella F, Kocialkowski S, et al. The distribution of the deleted in colon cancer (DCC) protein in human tissues. Cancer Res 1995; 55:5628-31.
37. Lawlor KG, Narayanan R. Persistent expression of the tumor suppressor gene DCC is essential for neuronal differentiation. Cell Growth Differ 1992;3:609-16.
38. Pierceall WE, Cho KR, Getzenberg RH, et al. NIH3T3 cells expressing the deleted in colorectal cancer tumor suppressor gene product stimulate neurite outgrowth in rat PC12 pheochromocytoma cells. J Cell Biol 1994;124:1017-27.
39. Narayanan R, Lawlor KG, Schaapveld RQ, et al. Antisense RNA to the putative tumor-suppressor gene DCC transforms Rat-1 fibroblasts. Oncogene 1992;7:553-61.
40. Shibata D, Rieger KM, Hess DT, Summerhayes IC, Steele G Jr. Disruption of DCC expression results in the acquisition of metastatic cell behavior. Surg Forum 1995;46:526-7.
41. Klingelhutz AJ, Hedrick L, Cho KR, McDougall JK. The DCC gene suppresses the malignant phenotype of transformed human epithelial cells, Oncogene 1995;10:1581-6.
42. Keino-Masu K, Masu M, Hinck L, et al. Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell 1996;87:175-85.
43. Chan SS-Y, Zheng H, Su M-W, et al. UNC-40, a C. elegans homolog of DCC (Deleted in Colorectal Cancer), is required in motile cells responding to UNC-6 netrin cues. Cell 1996;87:187-95.
44. Kolodziej PA, Timpe LC, Mitchell KJ, et al. Frazzled encodes a drosophila member of the DCC immunoglobulin subfamily and is required for CNS and motor axon guidance. Cell 1996;87:197-204.
45. Cho KR, Oliner JD, Simons JW, et al. The DCC gene: structural analysis and mutations in colorectal carcinomas. Genomics 1994;19:525-31.
46. Brabant G, Hoang-Vu C, Cetin Y, et al. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res 1993;53:4987-93.